\
&
Contact us
Background stories of how others approached and experienced their European Horizon funding trajectory.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
Read the full article for detailsPublished on • 1 year ago
These testimonials share at least one programme in common.
Funded under Horizon Europe (HORIZON-INFRA-2022-TECH-01) and running from 2023 to 2026, the ANERIS project aims to tackle the rapid loss of ocean biodiversity. The project’s main objective is to develop, test and implement the next generation of scientific instrumentation tools and methods for sensing and monitoring marine-life. Another key concept of the project is the introduction of the concept of Operational Marine Biology (OMB) as a biodiversity information system. The project consortium consists of 25 partners from 13 countries. Read more about the project and the contribution of Flemish partner VLIZ in this testimonial.